The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with an anti-amyloid monoclonal antibody (mAb), in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease.
Regimen A will evaluate the safety and efficacy of AADvac1, alone or in combination with an anti-amyloid mAb.
Phase:
PHASE2
Details
Lead Sponsor:
Paul S. Aisen
Collaborators:
Alzheimer's Clinical Trials Consortium Alzheimer's Therapeutic Research Institute Axon Neuroscience SE Massachusetts General Hospital National Institute on Aging (NIA) University of California, San Francisco